Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from SKAN Group AG ( (CH:SKAN) ) is now available.
SKAN Group has announced a CEO transition, with Jonas Greutert set to take over from Thomas Huber on January 1, 2026. Under Huber’s leadership, SKAN became a world leader in isolator systems for aseptic production, achieving significant sales growth and international expansion. Greutert, with a strong background in pharmaceutical technology and industrial automation, is expected to continue this growth trajectory, focusing on business expansion, profitability, and innovation.
The most recent analyst rating on (CH:SKAN) stock is a Buy with a CHF80.00 price target. To see the full list of analyst forecasts on SKAN Group AG stock, see the CH:SKAN Stock Forecast page.
More about SKAN Group AG
SKAN is a pioneer in aseptic and aseptic-toxic manufacturing processes for the biopharmaceutical industry. It is a market and technology leader in high-quality isolator systems for drug filling under strict sterility standards. The company also provides process support, services, and consumables, serving as a key partner for pharmaceutical and biotech industries, CMOs, and research labs worldwide. Founded in 1968, SKAN employs over 1600 people, with headquarters in Allschwil, Switzerland, and subsidiaries across several countries.
Average Trading Volume: 23,900
Technical Sentiment Signal: Sell
Current Market Cap: CHF1.38B
Find detailed analytics on SKAN stock on TipRanks’ Stock Analysis page.